Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
OKYO Pharma Limited is a biotechnology company focused on developing innovative therapies for ocular diseases, particularly dry eye disease and other inflammatory conditions. The company operates primarily in the UK and is advancing its lead product candidate, OK-101, which targets the underlying causes of dry eye disease, differentiating itself through its proprietary drug delivery system.
OKYO Pharma's business model revolves around the development of its lead drug candidate, OK-101, which is designed to provide a novel treatment for dry eye disease. The company aims to monetize its innovations through product sales upon successful commercialization and potential licensing agreements with larger pharmaceutical companies.
Progress in clinical trials for OK-101, particularly Phase II results
Partnership announcements or licensing deals with larger pharmaceutical firms
Regulatory approvals from health authorities such as the FDA or EMA
Market sentiment regarding the biotechnology sector
Regulatory changes impacting drug approval processes
Technological disruption in drug delivery systems
Emergence of alternative treatments for dry eye disease
Increased competition from larger pharmaceutical companies
High cash burn rate leading to potential liquidity issues
Dependence on external funding for R&D
low - The biotechnology sector is generally less sensitive to economic cycles as demand for healthcare remains relatively stable regardless of economic conditions.
Interest rates can affect OKYO Pharma's ability to raise capital for R&D, as higher rates increase the cost of financing. However, the company is currently not generating revenue, making it less sensitive to interest rate fluctuations in the short term.
minimal - The company has a negative debt/equity ratio, indicating it is not reliant on debt financing.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has exhibited significant volatility, with a 1-year return of -51.7%.
